Patients with certain KLK-6 mutations at risk for aggressive forms of prostate cancer

A newly published article in the Journal of the National Cancer Institute has suggested that men carrying a particular genetic mutation in the kallikrein 6 gene (KLK-6) have an increased risk for aggressive, clinically significant prostate cancer. … READ MORE …

The cost and the effectiveness of genomic testing for prostate cancer risk

As regular readers will be well aware, there are now several different tests available that can be used to assess risk for low- and very low-risk forms of prostate cancer at time of diagnosis (as opposed to clinically significant forms that need early treatment). … READ MORE …

Just how accurate are current genetic/genomic tests in the diagnosis and prognosis of prostate cancer?

As we have pointed out regularly over the years, all prostate cancers are by no means the same. And a recently published paper in European Urology makes the inherent diversity in the subtypes of prostate cancer even clearer — even within any one specific patient. … READ MORE …

Informed patient counseling and the effect on PSA testing

We know that a family history of prostate cancer and the presence of certain genetic/genomic markers are associated with increased risk for prostate cancer in general and for some types of clinically significant prostate cancer in particular. … READ MORE …

Individualizing precision therapy for advanced prostate cancer

There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be “tailor-made” for individualized, precision cancer therapy. … READ MORE …

Genetic ethnic ancestry and risk for prostate cancer diagnosis

It is becoming increasingly evident that there is a strong association between ethnic ancestry and risk for prostate cancer — at least among members of the US population. … READ MORE …

“Direct to consumer” testing for selected genes and risk for prostate cancer

We have noted previously that individualized genetic tests sold directly to consumers and patients as tools to assess risk for prostate cancer (and other disorders) often don’t meet FDA guidelines for marketing in the USA. Now there are more questions about the value of such tests. … READ MORE …